Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$16.15
-2.8%
$18.26
$14.15
$20.68
$2.69B0.541.83 million shs329,528 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$108.09
-1.5%
$120.62
$64.11
$139.13
$5.27B0.88659,160 shs187,677 shs
Organon & Co. stock logo
OGN
Organon & Co.
$14.60
-0.8%
$15.26
$13.87
$23.10
$3.77B0.762.55 million shs934,419 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.98
-3.3%
$26.34
$23.14
$33.46
$3.68B0.481.49 million shs480,746 shs
10 Stocks Set to Soar in Spring 2025 Cover

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+1.84%-2.41%-8.48%-10.93%-8.23%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.72%-7.90%-13.68%+25.69%+47.20%
Organon & Co. stock logo
OGN
Organon & Co.
+4.43%+0.24%+2.72%-1.47%-18.70%
Perrigo Company plc stock logo
PRGO
Perrigo
+0.85%+1.99%-3.63%+7.35%-10.89%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
4.0578 of 5 stars
4.31.00.00.02.14.22.5
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.7464 of 5 stars
4.53.00.04.51.94.20.6
Organon & Co. stock logo
OGN
Organon & Co.
4.8043 of 5 stars
3.21.03.33.73.51.73.1
Perrigo Company plc stock logo
PRGO
Perrigo
4.8394 of 5 stars
2.15.04.23.53.22.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.50
Moderate Buy$23.9348.19% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.00
Buy$167.6455.10% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.43
Hold$20.8042.47% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0022.31% Upside

Current Analyst Ratings Breakdown

Latest OGN, PRGO, ACAD, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
4/1/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$153.00 ➝ $153.00
3/27/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$212.00 ➝ $216.00
3/7/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight$20.00 ➝ $20.00
3/6/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
3/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$153.00 ➝ $153.00
3/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$132.00 ➝ $160.00
2/27/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$28.00 ➝ $28.00
2/27/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
2/27/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
2/27/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$125.00 ➝ $190.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$957.80M2.81N/AN/A$2.63 per share6.14
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M13.67N/AN/A$1.18 per share91.60
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.59$4.68 per share3.12($0.27) per share-54.07
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.84$5.63 per share4.79$35.19 per share0.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-$61.29M$1.3620.7121.25N/A13.83%25.83%14.71%5/6/2025 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.99N/A38.33N/A-74.47%-223.51%-39.88%5/5/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$3.334.383.900.9013.49%431.62%8.03%5/1/2025 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$12.70M-$1.25N/A8.82N/A-3.64%7.38%3.18%5/6/2025 (Estimated)

Latest OGN, PRGO, ACAD, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.92N/AN/AN/A$1.53 billionN/A
2/27/2025Q4 2024
Perrigo Company plc stock logo
PRGO
Perrigo
$0.92$0.93+$0.01-$0.32$1.20 billion$1.14 billion
2/18/2025Q4 2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.97-$0.96+$0.01-$1.54$117.83 million$118.77 million
2/13/2025Q4 2024
Organon & Co. stock logo
OGN
Organon & Co.
$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$1.127.67%+25.99%33.63%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.30%+4.77%N/A 23 Years

Latest OGN, PRGO, ACAD, and AXSM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/19/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.68%3/7/20253/7/20253/25/2025
2/13/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.287.3%2/24/20252/24/20253/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.29
2.11
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.22
2.11
2.04
Organon & Co. stock logo
OGN
Organon & Co.
17.73
1.70
1.21
Perrigo Company plc stock logo
PRGO
Perrigo
0.94
2.56
1.77

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
28.30%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.40%
Organon & Co. stock logo
OGN
Organon & Co.
1.40%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510166.79 million119.30 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38048.77 million37.84 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000257.95 million253.93 millionNot Optionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,900136.46 million135.47 millionOptionable

Recent News About These Companies

What is Zacks Research's Forecast for Perrigo Q1 Earnings?
Perrigo Co PLC (PRGO) Shares Up 0.11% on Mar 19

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$16.15 -0.47 (-2.83%)
As of 11:51 AM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$108.09 -1.66 (-1.51%)
As of 11:51 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$14.60 -0.12 (-0.82%)
As of 11:52 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.98 -0.93 (-3.33%)
As of 11:51 AM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.